ACHC · Acadia Healthcare Company, Inc.

Current Thesis

The read on ACHC has flipped from "broken-chart value trap waiting on a binary print" to "operational turnaround that is actually printing." The Q1 2026 report (2026-04-29) was clean revenue $828.8M (+7.6% YoY), same-facility revenue +7.3% (1.6% more patient days, 5.6% higher revenue/day), acute inpatient psych revenue $470.7M (+14% YoY) and management raised full-year guidance to revenue $3.37–3.45B / adj. EBITDA $580–615M / adj. EPS $1.35–1.60. A second sell-side house then upgraded: Jefferies to Buy from Hold, PT $30 from $24.50 (2026-06-03), joining UBS's Buy / PT $31 (2026-04-17). That is two clustered upgrades plus a guide raise under new management genuine narrative confirmation. But the explosive leg already happened: the stock ran from a 52-week low of $11.43 to ~$26 before stalling in the mid-$20s. This is a MATURING turnaround, not an accelerating discovery. Upside to the $30–31 PT cluster is ~22–27% from the $24.48 close (2026-06-05), capped by an unresolved DOJ/SEC probe and a fresh $105M jury verdict (2026-05-12). legacy-pivot, MEDIUM conviction on a pullback.

Bull Case

• Clean Q1 + guide raise (2026-04-29): Revenue $828.8M, +7.6% YoY; acute inpatient psych $470.7M, +14% YoY; FY26 guidance lifted to revenue $3.37–3.45B / adj. EBITDA $580–615M / adj. EPS $1.35–1.60. The print management itself characterized as a beat-and-raise the de-risking event the prior DORMANT read demanded.
• Two clustered Buy upgrades: UBS Buy / PT $31 (2026-04-17) and Jefferies Buy from Hold / PT $30, up from $24.50 (2026-06-03). Jefferies explicitly cited new management bringing operational stability and earnings visibility, plus ramp potential at beds added in the last three years.
• Florida Directed Payment Program approval is a concrete, identified forward catalyst Jefferies flagged it as fuel for a further guidance raise at the Q2 release. This is a dated, observable driver, not a vague "demand tailwind."
• Demand backdrop intact: acute psych volume +14% YoY confirms behavioral-health demand is real, not narrative. A 250+ facility footprint is not replicable; normalized margins against the $580–615M EBITDA guide imply real FCF power versus a $2.25B market cap (2026-06-05).
• Recovery structure already built: the stock has roughly doubled off the $11.43 low (52-wk range $11.43–$30.20), meaning the bottoming process and the first institutional re-accumulation leg are behind it, not ahead.

Bear Case

• $105M jury verdict (2026-05-12): subsidiary Fashion Valley CTC hit with $35M compensatory + $70M punitive in a retaliatory-termination case. Acadia plans post-trial motions and appeal, but ad-hoc coverage noted the verdict "shocked the market after strong earnings" a fresh, discrete overhang layered on top of the older probe.
• DOJ + SEC investigations remain open per the 2025 annual report; the company spent $135M in legal fees in 2025. The 2024 ~$20M Medicare-fraud settlement (with FL/GA/MI/NV) was a separate, closed matter it did not resolve the active federal probes. A charging decision or consent decree is a -20%+ single-session tail with no edge on timing.
• Move is mature, not accelerating: at $24.48 (2026-06-05) the stock is ~19% below the $30.20 high and only ~22–27% from the $30–31 PT cluster. The asymmetry that existed at $11–14 is gone; this is grind-to-target, not a fresh parabola.
• Sector is a laggard: healthcare services has trailed AI/industrial/defense for multiple years. Behavioral-health peers (UHS, HCA's psych unit) are not providing a group lift any ACHC move is idiosyncratic and must be carried by company-specific execution.
• Reimbursement / leverage risk: CMS policy on IMD exclusion and 1115 waivers cuts both ways; the same directed-payment mechanism (Florida DPP) that helps can be clawed back elsewhere. The operator carries debt, so the 2026-06-03 rate-hike-bet tape (S&P/Nasdaq off records) is a headwind to a leveraged name.

Setup & Price Structure

• Last: $24.48 close (2026-06-05, -2.9% on the day), $24.96 after-hours; $25.96 on 2026-06-03 (Jefferies upgrade day, intraday $25.10–$26.13). Market cap $2.25B.
• 52-week range $11.43–$30.20. Price sits roughly mid-range ~115% above the low, ~19% below the high. The recovery uptrend off the $11 bottom is intact, but price has stalled in the mid-$20s and faded the upgrade-day spike rather than breaking out.
• No clean breakout yet: the upgrade pushed it to ~$26 and it gave back ground within two sessions. The mid-$20s is a consolidation shelf below the $30.20 prior high / PT cluster, not a launch base.
• Levels that matter: $30.20 is the wall (52-wk high, coincident with the $30–31 analyst PTs). The low-$20s is the rising-trend / 20-EMA support zone built since the spring recovery. A weekly close back under ~$22, and especially a loss of the $20 handle, breaks the recovery structure and reverts this to the value-trap profile.
• Entry stance: for a MATURING turnaround the playbook entry is a pullback into rising MA support, which the fade from $26 to $24.48 partially offers a MEDIUM-sized probe, not a chase. Do not average down if the low-$20s gives way; re-seat only on a weekly reclaim of the mid-$20s on volume.
• absence keeps this MEDIUM.

Catalyst Calendar (next 30 days)

• No hard binary inside the next 30 days. The nearest scheduled event sits beyond the window.
• ~2026-07-29, est. Q2 2026 earnings (Q1 landed 2026-04-29; Acadia's Q2 historically prints late July). This is the key event: the Florida Directed Payment Program benefit and any second guide raise show up here. A 3-trading-day pre-print blackout applies as it approaches.
• Ongoing post-trial motions on the $105M Fashion Valley verdict (filed off the 2026-05-12 award). No fixed date; any 8-K reducing, staying, or upholding the award is a discrete mover.
• Open-ended DOJ/SEC probe status. No scheduled date; monitored via 8-K. Any charging language, consent decree, or favorable resolution is the largest single-session swing factor.

What Would Change Our Mind

• Bullish escalation → upgrade conviction toward HIGH: a weekly close that clears the mid-$20s shelf and reclaims toward $27–28 on ≥1.5x average volume, ideally paired with a third clustered upgrade or confirmed unusual call flow into the Q2 print. A Q2 release (~late July) that raises guidance a second time on Florida DPP would convert "turnaround working" into "narrative re-accelerating."
• Bearish invalidation → hard skip / stop: a weekly close below the low-$22 recovery-trend / 20-EMA zone, or any loss of the $20 handle (recovery structure broken). A DOJ/SEC charging or consent-decree 8-K. The $105M verdict being upheld or expanded on appeal. A Q2 print that fails to raise guidance despite the Florida DPP approval that would mean the operational story is not compounding.
• Discipline note: this is the archetype that burns momentum capital when forced cheap multiple + cratered-then-recovered chart + "upgrade." It is a MEDIUM probe only because the print and the second upgrade are real; it is not a fat pitch and must not be sized as one.

Correlation Notes

• Idiosyncratic-dominant. ACHC moves on its own legal and operational news (Q1 print, $105M verdict, DOJ/SEC headlines) far more than on sector beta. Peer read-through from UHS and HCA's psych segment is weak those names trade fine while ACHC carries a litigation discount.
• Policy-correlated: sensitive to CMS reimbursement policy (IMD exclusion, 1115 waivers, state directed-payment programs). The Florida DPP is a same-mechanism positive; a different state's clawback would be a same-mechanism negative.
• Rate-sensitive: as a leveraged hospital operator, ACHC is exposed to the rate-hike-bet regime flagged 2026-06-03 (S&P 500 / Nasdaq 100 off records, oil climbing). Higher-for-longer pressures the multiple even if operations improve.
• Sector context: healthcare services remains a multi-year laggard versus AI/industrial/defense leadership no rotation tailwind is supporting this, so the trade lives or dies on company-specific execution into the Q2 catalyst.